Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules.

Bid is a key member of the Bcl-2 family proteins involved in the control of the apoptotic cascade in cells, leading to cell death. Uncontrolled cell death is associated with several human pathologies, such as neurodegenerative diseases and ischemic injuries. Therefore, Bid represents a potential yet unexplored and challenging target for strategies aimed at the development of therapeutic agents. Here we show that a multidisciplinary NMR-based approach that we named SAR by ILOEs (structure activity relationships by interligand nuclear Overhauser effect) allowed us to rationally design a series of 4-phenylsulfanyl-phenylamine derivatives that are capable of occupying a deep hydrophobic crevice on the surface of Bid. These compounds represent the first antiapoptotic small molecules targeting a Bcl-2 protein as shown by their ability to inhibit tBid-induced SMAC release, caspase-3 activation, and cell death.

[1]  R. London,et al.  Interligand Overhauser effects in type II dihydrofolate reductase. , 2001, Biochemistry.

[2]  R. Clark,et al.  Consensus scoring for ligand/protein interactions. , 2002, Journal of molecular graphics & modelling.

[3]  Thomas Lengauer,et al.  Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.

[4]  K Wüthrich,et al.  A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules. , 1980, Biochemical and biophysical research communications.

[5]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[6]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[7]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[8]  R. London,et al.  The inter-ligand Overhauser effect: A powerful new NMR approach for mapping structural relationships of macromolecular ligands , 1999, Journal of biomolecular NMR.

[9]  A. Godzik,et al.  Characterization of the anti-apoptotic mechanism of Bcl-B. , 2003, The Biochemical journal.

[10]  Yahong Lin,et al.  A JNK-Dependent Pathway Is Required for TNFα-Induced Apoptosis , 2003, Cell.

[11]  Wolfgang Jahnke,et al.  Second-site NMR screening and linker design. , 2003, Current topics in medicinal chemistry.

[12]  Ziwei Huang,et al.  The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules. , 2002, Chemistry & biology.

[13]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[14]  Robert M Friedlander,et al.  Apoptosis and caspases in neurodegenerative diseases. , 2003, The New England journal of medicine.

[15]  Feng Ni,et al.  Recent developments in transferred NOE methods , 1994 .

[16]  A. Ganesan,et al.  Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. , 2004, Current medicinal chemistry.

[17]  V. Mootha,et al.  tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. , 2000, Genes & development.

[18]  A. Kamal,et al.  Design, synthesis, and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity. , 2002, Journal of medicinal chemistry.

[19]  S. Korsmeyer,et al.  Caspase Cleaved BID Targets Mitochondria and Is Required for Cytochrome c Release, while BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death* , 1999, The Journal of Biological Chemistry.

[20]  T. Mitchison,et al.  Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL , 2001, Nature Cell Biology.

[21]  D. Hockenbery,et al.  Bcl-2-related proteins as drug targets. , 2003, Current medicinal chemistry.

[22]  M. Vila,et al.  Instrumental Activation of Bid by Caspase-1 in a Transgenic Mouse Model of ALS , 2002, Molecular and Cellular Neuroscience.

[23]  J. Martinou,et al.  The Bcl-2 protein family. , 2000, Experimental cell research.

[24]  Maurizio Pellecchia,et al.  NMR-based structural characterization of large protein-ligand interactions , 2002, Journal of biomolecular NMR.

[25]  John Calvin Reed,et al.  Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.

[26]  Luca Scorrano,et al.  Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. , 2003, Biochemical and biophysical research communications.

[27]  John Calvin Reed,et al.  Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. , 2003, Cancer research.

[28]  N. Wahlgren,et al.  Mechanisms of action of neuroprotectants in stroke. , 2000, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[29]  S. Korsmeyer,et al.  Solution Structure of the Proapoptotic Molecule BID A Structural Basis for Apoptotic Agonists and Antagonists , 1999, Cell.

[30]  John C Reed,et al.  Bcl-2 family proteins , 1998, Oncogene.

[31]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[32]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[33]  Maurizio Pellecchia,et al.  Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL , 2004 .

[34]  Kam Y. J. Zhang,et al.  Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 , 2001, Nature Cell Biology.

[35]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[36]  Junying Yuan,et al.  Solution Structure of BID, an Intracellular Amplifier of Apoptotic Signaling , 1999, Cell.

[37]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins , 1997, Science.

[38]  R. Riek,et al.  Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Korsmeyer,et al.  Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c , 2000, Cell Death and Differentiation.

[40]  B. Antonsson,et al.  Two pathways for tBID‐induced cytochrome c release from rat brain mitochondria: BAK‐ versus BAX‐dependence , 2002, Journal of neurochemistry.

[41]  J Brickmann,et al.  Texture mapping: a new tool for molecular graphics. , 1994, Journal of Molecular Graphics.

[42]  J. Preston,et al.  A RAPID SYNTHESIS OF OLIGOPEPTIDE DERIVATIVES WITHOUT ISOLATION OF INTERMEDIATES. , 1965, Journal of the American Chemical Society.

[43]  Ajay,et al.  The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.

[44]  Oliver Zerbe.  BioNMR in drug research , 2003 .

[45]  J C Reed,et al.  Ion Channel Activity of the BH3 Only Bcl-2 Family Member, BID* , 1999, The Journal of Biological Chemistry.

[46]  S. Korsmeyer,et al.  Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis , 1999, Nature.

[47]  P. Waldmeier.  Prospects for antiapoptotic drug therapy of neurodegenerative diseases , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[48]  T. Chittenden.  BH3 domains: intracellular death-ligands critical for initiating apoptosis. , 2002, Cancer cell.

[49]  Kurt Wüthrich,et al.  Nmr in drug discovery , 2002, Nature Reviews Drug Discovery.

[50]  M. Degli Esposti,et al.  The roles of Bid , 2002, Apoptosis.

[51]  B. Meyer,et al.  Mapping the active site of angiotensin-converting enzyme by transferred NOE spectroscopy. , 2000, Journal of medicinal chemistry.